Month: March 2023

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Received $25 million equity investment from Pfizer, and entered into clinical development collaboration with Pfizer for a potential Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma Cash and investments of $228.2 million expected to fund operating plan into first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022. “We...

Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponsored trial with hypoimmune-modified primary islet cells with potential clinical data this year Goal to submit two INDs this year for SC262 and SG299 Targeting multiple additional INDs in 2024 Q4 2022 cash position of $434.0 million Current cash position enables for runway into 2025 SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022. “2022 began our transformation from a research focused organization to a clinical-stage company, setting the stage for important clinical data in 2023 and 2024 to...

Company to host conference call March 16, 2023, at 4:30 PM EDT SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2022 financial results and provided an update on the cytisinicline development program. Recent HighlightsPresented additional analyses from the Phase 3 ORCA-2 trial at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting Announced accomplishment of key milestones, including last subject dosing and last subject visit, in the Phase 2 ORCA-V1 trial evaluating cytisinicline for e-cigarette cessation Completed dosing of...

–Record Full Year Gross Margin with Continued Margin Expansion– CHINO, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat”), a specialty distributor and manufacturer of disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 HighlightsNet sales of $92.7 million, up 1.5 percent from the prior-year quarter. Gross profit of $29.7 million, negatively impacted by an out-of-period inventory write-off of $1.7 million, up 4.8 percent from the prior-year quarter. Gross margin of 32.0 percent, an improvement of 100 basis points over the prior-year quarter. Net income of $4.5 million (net income margin of 4.9 percent), versus $6.0 million (net income margin of 6.5 percent) in the prior-year...

– Robust Pipeline in Life Sciences Sector Positions Business for Growth in 2023 – – Significantly Reduced SG&A in The Quarter and Year – – 58% Reduction in Net Loss and Slight Adjusted EBITDA Loss in The Fourth Quarter Reflect Operating Leverage In Business Model As Company Scales – FREDERICK, Md., March 16, 2023 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the fourth quarter and year ended December 31, 2022. TOMI Chief Executive Officer, Dr. Halden Shane, stated, “2022 delivered continued growth in our revenue and sales pipeline as well as improved year over year financial operating...

– Q4 revenue up 9% quarter over quarter to $44.3 million – – FY 2022 cash from operations up significantly to $8.6 million, compared to cash used of $8.6 million in FY 2021 – – Recently completed refinancing of legacy debt, reducing principal debt outstanding by nearly half – PHOENIX, March 16, 2023 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO:TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is reporting its financial and operating results for the three and twelve months ended December 31, 2022. All financial information is reported in U.S. dollars and prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”)...

Completes Integration, Validates Breakthrough Technologies, Proves Commercial Readiness of Technologies VIRGINIA CITY, Nev., March 16, 2023 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”), an innovator of technologies that enable systemic decarbonization, today announced its full year 2022 results, summary of achievements completed in 2022, and our 2023 business outlook. “During 2022, we integrated our acquisitions, achieved extraordinary technological breakthroughs, advanced each business, and monetized non-strategic assets,” said Corrado De Gasperis, Comstock’s executive chairman and chief executive officer. Selected Strategic Highlights from 2022 The following is a selection of strategic highlights from the year: Cellulosic Fuels “Our renewable fuels team recently demonstrated commercial readiness...

Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business update. Highlights for the fourth quarter of 2022 and recent weeks include:Based upon encouraging safety findings from its ongoing Phase 1 program, Onconova intends to administer narazaciclib orally with a continuous daily dosing schedule in upcoming clinical trials. Results from the Phase 1 solid tumor trial evaluating a continuous daily dosing regimen of narazaciclib showed that the maximum tolerated dose was not reached through the fifth dose...

Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022. Sujal Shah, President and CEO of CymaBay, stated, “We are off to a fast start in 2023 after making significant progress in 2022 in our development program evaluating seladelpar for patients with primary biliary cholangitis (PBC). Since completing enrollment in RESPONSE, our global phase 3 registration study, in July 2022, we presented data at The Liver MeetingÒ, licensed rights to develop and commercialize seladelpar for patients with PBC in Japan...

Announces Strategic Restructuring and Elimination of $15 Million of Costs; Simplifying Core Business Around Playboy and Honey Birdette LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today provided financial results for the fourth quarter and full year ended December 31, 2022. Comments from Ben Kohn, Chief Executive Officer of PLBY Group “Last year was challenging on a number of fronts. We embarked on a strategic review to restructure and simplify our business. We have reduced leverage and are evolving our strategy to move to a capital light model entirely focused on our most valuable brands, Playboy and Honey Birdette. This restructuring...